SIU Congress 2016: Using pathway analysis and metabolic signature to predict survival in MIBC - Session Highlights


Buenos Aires, Argentina (UroToday.com) Seth Lerner, Professor Baylor College of Medicine, discussed metabolomics and bladder cancer. Biological processed are associated with tumor progression yet poorly understood.


With environmental influences including smoking and other known carcinogens metabolomics needs to be explored. Metabolomics is the comparative analysis of endogenous metabolites found in biological samples. Distinct metabolomic profiles exist in bladder cancer which have been validated and enhanced discriminatory power when compared to urine cytology at detecting bladder cancer. Metabolic signatures have been associated with survival in patients who have undergone radical cystectomy. Moreover, metabolomics maps have been developed to understand new pathways and ultimately create a gene panel to apply in the clinical setting which has been shown to be associated with survival outcomes in external datasets. In summary, metabolomics can help identify actionable amino acid targets in future studies.

World Urological Oncology Federation Symposium at the SIU Congress 2016 - October 20 - 23, 2016 – Buenos Aires, Argentina

Written By: Stephen B. Williams, M.D., Assistant Professor in Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.